PRKCD and neoplasm: Lastly, the loss of PKCδ has been shown to increase Ag presenting competence in macrophages and DCs and trigger type I and type II interferon signaling, proposing PKCδ that is a reasonable target to reprogram mononuclear phagocytes and increase intra-tumor T cell migration while improving the PD-1 blockade efficacy [303].